吉西他滨联合奥沙利铂治疗晚期胰腺癌35例

Gemcitabine combined with Oxaliplatin in the treatment of 35 patients with advanced pancreatic cancer

目的:探讨吉西他滨联合奥沙利铂治疗晚期胰腺癌的近期疗效和安全性。方法:2006年3月～2010年3月,我院将经病理组织学证实的70例晚期胰腺癌患者随机分为吉西他滨联合奥沙利铂治疗组(观察组)和单用吉西他滨治疗组(对照组),各35例。结果:观察组有效26例(74.30%),临床受益29例(82.90%),11例(31.40%)生存期超过1年,中位生存期为7.5个月;对照组有效14例(40.00%),临床受益20例(57.10%),仅1例(2.86%)生存期超过1年,中位生存期为4.3个月。两组比较差异有统计学意义(P<0.05)。不良反应主要为白细胞下降及胃肠道反应。结论:吉西他滨联合奥沙利铂治疗晚期胰腺癌的近期疗效优于单用吉西他滨。

Objective： To evaluate the short-term effect and safety of Gemcitabine combined with Oxaliplatin in the treatment of advanced pancreatic cancer.Methods： From March 2006 to March 2010,70 patients with advanced pancreatic cancer admitted in our hospital confirmed by histopathology were randomly divided into Gemcitabine combined with Oxaliplatin treatment group（observation group） and Gemcitabine alone treatment group（control group）,with 35 patients in each group.Results： In the observation group,26 patients（74.30%） were effective,29（82.90%） got clinical benefit,11（31.40%） survived over one year,the median survival was 7.5 months;in the control group,14（40.00%） were effective,20（57.10%） got clinical benefit,only 1（2.86%） survived over one year,the median survival was 4.3 months.The difference was significant（P0.05）.Main side effects were leucopenia and gastrointestinal reactions.Conclusion： The short-term effect of Gemcitabine combined with Oxaliplatin in the treatment of advanced pancreatic cancer is better than that of Gemcitabine alone.